Hap10 Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Hap10 General Information

Description

Developer of antibody immunotherapies designed for treating resistance to covalent inhibitors of oncoproteins. The company is developing drug which can stop the cancer from growing, enabling oncologists to provide therapies for patients suffering from aggressive cancers.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2309 55th Street
  • Court North West
  • Gig Harbor, WA 98335
  • United States
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Pharmaceuticals
Vertical(s)
Corporate Office
  • 2309 55th Street
  • Court North West
  • Gig Harbor, WA 98335
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hap10 Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 28-Feb-2024 Completed Out of Business
1. Early Stage VC 01-Mar-2023 Completed Startup
To view Hap10’s complete valuation and funding history, request access »

Hap10 FAQs

  • When was Hap10 founded?

    Hap10 was founded in 2022.

  • Where is Hap10 headquartered?

    Hap10 is headquartered in Gig Harbor, WA.

  • What industry is Hap10 in?

    Hap10’s primary industry is Drug Discovery.

  • Is Hap10 a private or public company?

    Hap10 is a Private company.

  • What is Hap10’s current revenue?

    The current revenue for Hap10 is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process